Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -15.63 Million USD | 10.92% |
| 2022 | -17.55 Million USD | -11991.04% |
| 2021 | -145.16 Thousand USD | -115.72% |
| 2020 | 923.23 Thousand USD | 36.76% |
| 2019 | 675.06 Thousand USD | -19.38% |
| 2018 | 837.38 Thousand USD | 20.52% |
| 2017 | 694.78 Thousand USD | 287.03% |
| 2016 | 179.51 Thousand USD | -83.53% |
| 2015 | 1.08 Million USD | 223.66% |
| 2014 | 336.7 Thousand USD | 1896.7% |
| 2013 | -18.74 Thousand USD | 73.28% |
| 2012 | -70.13 Thousand USD | -15.56% |
| 2011 | -60.69 Thousand USD | 62.63% |
| 2010 | -162.39 Thousand USD | -100.2% |
| 2009 | -81.11 Thousand USD | -741.84% |
| 2008 | 12.63 Thousand USD | 184.85% |
| 2007 | -14.89 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -16.82 Million USD | -7.59% |
| 2024 Q2 | -10.93 Million USD | 35.02% |
| 2023 Q1 | -18.55 Million USD | -5.74% |
| 2023 Q2 | -19.01 Million USD | -2.43% |
| 2023 FY | -15.63 Million USD | 10.92% |
| 2023 Q4 | -15.63 Million USD | 13.97% |
| 2023 Q3 | -18.17 Million USD | 4.41% |
| 2022 Q2 | -41.72 Million USD | -216.66% |
| 2022 FY | -17.55 Million USD | -11991.04% |
| 2022 Q3 | -40.55 Million USD | 2.81% |
| 2022 Q1 | -13.17 Million USD | -8977.56% |
| 2022 Q4 | -17.55 Million USD | 56.72% |
| 2021 FY | -145.16 Thousand USD | -115.72% |
| 2021 Q1 | 946.16 Thousand USD | 2.48% |
| 2021 Q3 | 1.14 Million USD | 44.76% |
| 2021 Q2 | 792.78 Thousand USD | -16.21% |
| 2021 Q4 | -145.16 Thousand USD | -112.65% |
| 2020 Q1 | 630.86 Thousand USD | -6.55% |
| 2020 FY | 923.23 Thousand USD | 36.76% |
| 2020 Q3 | 527.32 Thousand USD | -3.32% |
| 2020 Q4 | 923.23 Thousand USD | 75.08% |
| 2020 Q2 | 545.4 Thousand USD | -13.55% |
| 2019 FY | 675.06 Thousand USD | -19.38% |
| 2019 Q3 | 669.69 Thousand USD | -9.68% |
| 2019 Q2 | 741.5 Thousand USD | -35.21% |
| 2019 Q1 | 1.14 Million USD | 36.67% |
| 2019 Q4 | 675.06 Thousand USD | 0.8% |
| 2018 Q2 | 1.23 Million USD | -2.08% |
| 2018 Q3 | 864.13 Thousand USD | -30.13% |
| 2018 FY | 837.38 Thousand USD | 20.52% |
| 2018 Q1 | 1.26 Million USD | 81.78% |
| 2018 Q4 | 837.38 Thousand USD | -3.09% |
| 2017 Q1 | 238.18 Thousand USD | 32.68% |
| 2017 Q4 | 694.78 Thousand USD | 72.12% |
| 2017 Q2 | 275.72 Thousand USD | 15.76% |
| 2017 FY | 694.78 Thousand USD | 287.03% |
| 2017 Q3 | 403.66 Thousand USD | 46.4% |
| 2016 Q1 | 981.19 Thousand USD | -9.96% |
| 2016 FY | 179.51 Thousand USD | -83.53% |
| 2016 Q4 | 179.51 Thousand USD | -20.99% |
| 2016 Q3 | 227.2 Thousand USD | -9.2% |
| 2016 Q2 | 250.22 Thousand USD | -74.5% |
| 2015 FY | 1.08 Million USD | 223.66% |
| 2015 Q4 | 1.08 Million USD | 271.41% |
| 2015 Q2 | 233.41 Thousand USD | 41.95% |
| 2015 Q3 | 293.41 Thousand USD | 25.71% |
| 2015 Q1 | 164.43 Thousand USD | -51.16% |
| 2014 Q2 | 244.08 Thousand USD | 293.44% |
| 2014 FY | 336.7 Thousand USD | 1896.7% |
| 2014 Q1 | 62.04 Thousand USD | 431.06% |
| 2014 Q4 | 336.7 Thousand USD | 51.57% |
| 2014 Q3 | 222.14 Thousand USD | -8.99% |
| 2013 Q4 | -18.74 Thousand USD | 67.96% |
| 2013 Q3 | -58.48 Thousand USD | 59.42% |
| 2013 Q2 | -144.13 Thousand USD | 40.79% |
| 2013 Q1 | -243.41 Thousand USD | -247.05% |
| 2013 FY | -18.74 Thousand USD | 73.28% |
| 2012 Q4 | -70.13 Thousand USD | 71.13% |
| 2012 Q1 | -25.93 Thousand USD | 57.27% |
| 2012 Q2 | -50.74 Thousand USD | -95.65% |
| 2012 Q3 | -242.91 Thousand USD | -378.72% |
| 2012 FY | -70.13 Thousand USD | -15.56% |
| 2011 Q1 | -118.06 Thousand USD | 27.3% |
| 2011 Q3 | -178.47 Thousand USD | -76.29% |
| 2011 FY | -60.69 Thousand USD | 62.63% |
| 2011 Q4 | -60.69 Thousand USD | 65.99% |
| 2011 Q2 | -101.24 Thousand USD | 14.25% |
| 2010 Q3 | -108.14 Thousand USD | -563.85% |
| 2010 Q4 | -162.39 Thousand USD | -50.16% |
| 2010 Q2 | -16.29 Thousand USD | 44.1% |
| 2010 FY | -162.39 Thousand USD | -100.2% |
| 2010 Q1 | -29.14 Thousand USD | 0.0% |
| 2009 FY | -81.11 Thousand USD | -741.84% |
| 2009 Q3 | -179.84 Thousand USD | -692.32% |
| 2009 Q2 | 30.36 Thousand USD | 17.39% |
| 2009 Q1 | 25.86 Thousand USD | 23.53% |
| 2008 Q1 | 9109.00 USD | 286.66% |
| 2008 FY | 12.63 Thousand USD | 184.85% |
| 2008 Q3 | 20.02 Thousand USD | 58.46% |
| 2008 Q4 | 20.93 Thousand USD | 4.55% |
| 2008 Q2 | 12.63 Thousand USD | 38.74% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | -7895.00 USD | 0.0% |
| 2007 FY | -14.89 Thousand USD | 0.0% |
| 2007 Q4 | -4880.00 USD | 38.19% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 24.87 Million USD | 162.863% |
| Harrow Health, Inc. | 116.41 Million USD | 113.43% |
| Dynavax Technologies Corporation | 106.63 Million USD | 114.662% |
| Biofrontera Inc. | 4.05 Million USD | 485.469% |
| Cronos Group Inc. | -663.32 Million USD | 97.643% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -520.422% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 102.508% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -7.292% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -201.476% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 14731.095% |
| Radius Health, Inc. | 359.28 Million USD | 104.352% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 8027.956% |
| DURECT Corporation | -7.65 Million USD | -104.268% |
| ProPhase Labs, Inc. | 19.23 Million USD | 181.299% |
| Safety Shot Inc | -2.28 Million USD | -584.417% |
| Phibro Animal Health Corporation | 454.84 Million USD | 103.437% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -65.802% |
| Alvotech | 1.06 Billion USD | 101.469% |
| Assertio Holdings, Inc. | -32.52 Million USD | 51.936% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 53.367% |
| Rockwell Medical, Inc. | 4.45 Million USD | 450.867% |
| Procaps Group S.A. | 242.93 Million USD | 106.436% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 88.05% |
| SCYNEXIS, Inc. | -19.35 Million USD | 19.201% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -220.579% |
| Viatris Inc. | 17.13 Billion USD | 100.091% |
| OptiNose, Inc. | 58.06 Million USD | 126.926% |
| SIGA Technologies, Inc. | -148.68 Million USD | 89.484% |
| Tilray Brands, Inc. | 158.97 Million USD | 109.835% |
| PetIQ, Inc. | 351.93 Million USD | 104.443% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -0.0% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 108.818% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -145.841% |
| Alimera Sciences, Inc. | 55.3 Million USD | 128.268% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 103.591% |
| Silver Spike Investment Corp. | -32.61 Million USD | 52.058% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -950.206% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 204.141% |
| Journey Medical Corporation | -9.7 Million USD | -61.032% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -208.962% |
| Alpha Teknova, Inc. | 1.97 Million USD | 892.028% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -224.774% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 112.826% |
| PainReform Ltd. | -7.95 Million USD | -96.662% |
| Cosmos Health Inc. | 8.59 Million USD | 281.994% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 470.753% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 525.085% |
| Embecta Corp. | 1.31 Billion USD | 101.192% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -438.86% |
| Talphera, Inc. | -5.72 Million USD | -173.285% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 103.613% |
| Incannex Healthcare Limited | -5.48 Million USD | -185.044% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -90.354% |
| Shineco, Inc. | 29.29 Million USD | 153.378% |
| Procaps Group, S.A. | 242.93 Million USD | 106.436% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 116.596% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 120.86% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 83.833% |
| Alvotech | 1.06 Billion USD | 101.469% |
| Hempacco Co., Inc. | 13.61 Million USD | 214.837% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 318.819% |
| Bright Green Corporation | 1.84 Million USD | 948.913% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 103.408% |
| Kamada Ltd. | -46.43 Million USD | 66.328% |
| Indivior PLC | -33.95 Million USD | 53.951% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 6100.078% |
| Flora Growth Corp. | -713 Thousand USD | -2092.797% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -90.354% |
| Evolus, Inc. | 63.7 Million USD | 124.541% |
| HUTCHMED (China) Limited | -197.45 Million USD | 92.082% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 103.263% |
| Akanda Corp. | 3.9 Million USD | 500.384% |